ClinicalTrials.gg
CompletedNCT00971581Updated Jun 29, 2010

Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole

A Phase 3 interventional study of FDC KETOPROFEN+OMEPRAZOLE in Pain, sponsored by Sanofi. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-06-29.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Pain with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Pain · Mexico.

Enrollment
29th of 43
52 · median 160
Started
2009
with 2 others
Phase 3
10 of 44
none open now
Registered
13th of 44
by date
Lead sponsor
2 of 44
Sanofi

Among the 44 studies in Pain with a site in Mexico, this one is the 29th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 13th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

2 of the 44 studies in Pain with a site in Mexico are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Pain with a site in Mexico, or all of them as a file.
02

Study summary

Primary Objective:

To confirm the safety and tolerability of the fixed dose combination of a Non-Steroidal Anti-Inflammatory Drug (NSAID), ketoprofen, associated to a Proton Pump Inhibitor (PPI), omeprazole, in Mexican patients.

Secondary Objective:

To confirm the efficacy of the combination:

  • Relief of pain (Visual Analyzed Score (VAS))
  • Patients global assessment of disease activity, scored as a scale of 1 (no limitation of normal activities) to 5 (inability to carried out all normal activities)
03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults suffering from chronic inflammatory conditions, in particular, rheumatoid polyarthritis, ankylosing spondylitis (or related syndromes, such as, Reiters syndrome, psoriatic arthritis,) with a previous history or who are at risk of developing NSAID associated benign gastric ulcers, duodenal ulcers and gastroduodenal erosions in whom continued treatment with NSAIDs is necessary.
  • Presenting at the inclusion visit an acute episode of recent onset (\<48 hours) defined by average pain within the last 24 hours >=50 mm on the Visual Analogue Scale (VAS).

Exclusion criteria

Exclusion criteria:

  • to ketoprofen or to omeprazole or to another proton-pump inhibitor or to any of the .
  • Last trimester of pregnancy.
  • History of asthma induced by administration of ketoprofen or similar acting substances, such as other non-steroidal anti-inflammatory agents (NSAIDs) or acetylsalicylic acid.
  • Gastrointestinal disorder or surgery leading to impaired drug absorption.
  • Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the investigator's opinion would endanger a subject if they were to participate in the study.
  • Serious blood coagulation disorder including use of systemic anticoagulants.
  • Positive test result for H. pylori at screening.
  • Recent endoscopy showing any gastric or duodenal ulcer at least 3 mm in diameter with depth.
  • Severe hepatic failure.
  • Severe renal failure.
  • Severe heart failure.
  • Patients with asthma associated with chronic rhinitis, chronic sinusitis and/or nasal polyposis.
  • Active peptic ulcer.
  • Gastrointestinal bleeding, cerebrovascular bleeding or other active bleeding.
  • Alcohol consumption or drug abuse.
  • Concomitant use with St. Johns wort or atazanavir sulphate.
  • Concomitant use of the following medications:

    • NSAIDs including cyclooxygenase-2 selective inhibitors
    • Salicylates
    • DMARDs
    • Antacids
    • Histamine H2 receptors
    • Misoprostol
    • Other PPI
    • Sucralfate
    • Anticoagulants: Anti- agents and selective serotonin reuptake inhibitors (SSRIs)
    • Lithium:
    • Methotrexate (at doses above 15 mg/week):
  • Screening laboratory value for , AST >2 times the .
  • Other than noted specifically, any screening laboratory value that is in the investigator's opinion and would endanger a subject if they were to participate in the study.
  • History of , treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.
  • Participation in any study of an treatment in the 8 weeks before screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    FDC KETOPROFEN+OMEPRAZOLE

    One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks

    Drug: FDC KETOPROFEN+OMEPRAZOLE

Interventions

  • DrugFDC KETOPROFEN+OMEPRAZOLE

    Ketoprofen + Omeprazole FDC once daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. To confirm the efficacy of the combination

    Time frame: From the start to the end of the study (D 0 to D 28)

  2. Incidence of dyspeptic symptoms: epigastric pain, dyspepsia, nausea

    Time frame: At Day 10

Secondary outcomes

  1. Incidence of dyspeptic symptoms: epigastric pain, dyspepsia, nausea

    Time frame: At Day 0, Day 4 & Day 28

  2. Incidence of complications (perforations, ulcers, bleeding) and Incidence of fecal occult blood positivity

    Time frame: At study termination (Day 28)

  3. Improvement of pain (VAS)

    Time frame: At study termination (Day 28)

  4. Incidence of moderate to severe abdominal symptoms and GastroIntestinal Adverse Event leading to withdrawal

    Time frame: From the start to the end of the study (D 0 to D 28)

  5. Patient's global assessment of disease activity, scored as a scale of 1 (no limitation of normal activities) to 5 (inability to carried out all normal activities)

    Time frame: At study termination (Day 28)

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Col. Coyoacan, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2009
First posted
Sep 3, 2009
Start
Aug 2009
Primary completionActual
May 2010
CompletionActual
May 2010
Last update
Jun 29, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00971581
Lead sponsor
Sanofi
First posted
Sep 3, 2009
Start date
Aug 2009
Primary completion
May 2010
Completion
May 2010
Last update
Jun 29, 2010

Study contacts

Judith Diaz
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion